Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 15 h ago

Maze Therapeutics, Inc.: Third Rock Ventures IV, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Third Rock Ventures IV, L.P. amended its Schedule 13G beneficial ownership filing for Maze Therapeutics, Inc., disclosing the change to the SEC under accession number 0001193125-26-463548. The filing updates the venture firm's reported stake in the clinical-stage biotech, though the amended document did not specify a revised share count or percentage in the headline disclosure. The move matters because 13G amendments signal shifts in major institutional holdings that can influence governance and investor sentiment around thinly traded biotech names. Investors will watch for the full filing details to confirm whether Third Rock's position increased, decreased or was merely restated, and for any subsequent Form 4 insider activity.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Third Rock Ventures IV, L.P., Maze Therapeutics, Inc.